Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.49 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.49 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14325320 | 0.95 | CYP4F2 (0.55) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL12329630 | 0.94 | PPARA (0.56) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL765019 | 0.94 | PPARA (0.56) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL879289 | 0.90 | CYP4F2 (0.58) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL3946860 | 0.88 | TDP1 (0.49) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL19089791 | 0.88 | ALOX5 (0.57) | ALOX5PPARAPPARGTDP1CYP4F2 | |
| SCHEMBL28008684 | 0.87 | EPHX2 (0.52) | ALOX5PPARAPPARGTDP1 | |
| SCHEMBL3906464 | 0.86 | ALOX5 (0.56) | ALOX5PPARAPPARGCYP4F2CYP4A11 | |
| SCHEMBL13948868 | 0.86 | NPC1 (0.54) | TDP1CYP4F2CYP4A11KMT2ANPC1 | |
| SCHEMBL16673215 | 0.85 | PPARA (0.48) | ALOX5PPARAPPARGTDP1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-9676754-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150344446-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-9102599-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-11 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-18 | — | — | US | disclosed |
| US-8404896-B2 | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7652023-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-26 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-0525360-B1 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RES INST CHEM TECH (KR) | 1998-03-25 | — | — | EP | disclosed |
| US-5242944-A | Analgesics or antiinflammatory agents | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-09-07 | — | — | US | disclosed |
| EP-0525360-A2 | Novel phenylacetamide derivatives and processes for the preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666557-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | ALOX5 158/4885PPARA 1/4885PPARG 2/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | ALOX5 2761/4885PPARA 572/4885PPARG 1127/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALOX5 2439/4885PPARA 827/4885PPARG 890/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALOX5 2439/4885PPARA 827/4885PPARG 890/4885 |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | ALOX5 158/4885PPARA 1/4885PPARG 2/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALOX5 2439/4885PPARA 827/4885PPARG 890/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALOX5 2439/4885PPARA 827/4885PPARG 890/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | ALOX5 1937/4885PPARA 3959/4885PPARG 3706/4885 |
| US-20130184279-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | ALOX5 2690/4885PPARA 588/4885PPARG 1040/4885 |
| US-20150344446-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | ALOX5 158/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.